Ambar I, Kloog Y, Sokolovsky M
Department of Biochemistry, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel.
J Neurochem. 1988 Jul;51(1):133-40. doi: 10.1111/j.1471-4159.1988.tb04846.x.
Phencyclidine (PCP) receptors were successfully solubilized from rat forebrain membranes with 1% sodium cholate. Approximately 58% of the initial protein and 20-30% of the high-affinity PCP binding sites were solubilized. The high affinity toward PCP-like drugs, the stereo-selectivity of the sites, and the sensitivity to N-methyl-D-aspartate (NMDA) receptor ligands were preserved. Binding of the potent PCP receptor ligand N-[3H][1-(2-thienyl)cyclohexyl] piperidine ([3H]TCP) to the soluble receptors was saturable (KD = 35 nM), and PCP-like drugs inhibited [3H]TCP binding in a rank order of potency close to that observed for the membrane-bound receptors; the most potent inhibitors were TCP (Ki = 31 nM) and the anticonvulsant MK-801 (Ki = 50 nM). The NMDA receptor antagonist 2-amino-5-phosphonovaleric acid inhibited binding of [3H]TCP to the soluble receptors; glutamate or NMDA diminished this inhibition in a dose-dependent manner. Taken together, the results indicate that the soluble PCP receptor preparation contains the glutamate recognition sites and may represent a single receptor complex for PCP and NMDA, as suggested by electrophysiological data. The successful solubilization of the PCP receptors in an active binding form should now facilitate their purification.
用1%胆酸钠成功地从大鼠前脑细胞膜中溶解出苯环己哌啶(PCP)受体。初始蛋白质的约58%以及20 - 30%的高亲和力PCP结合位点被溶解。对PCP类药物的高亲和力、位点的立体选择性以及对N - 甲基 - D - 天冬氨酸(NMDA)受体配体的敏感性得以保留。强效PCP受体配体N - [³H][1 - (2 - 噻吩基)环己基]哌啶([³H]TCP)与可溶性受体的结合是可饱和的(KD = 35 nM),并且PCP类药物以与膜结合受体观察到的效力顺序相近的方式抑制[³H]TCP结合;最有效的抑制剂是TCP(Ki = 31 nM)和抗惊厥药MK - 801(Ki = 50 nM)。NMDA受体拮抗剂2 - 氨基 - 5 - 膦酰基戊酸抑制[³H]TCP与可溶性受体的结合;谷氨酸或NMDA以剂量依赖的方式减弱这种抑制作用。综上所述,结果表明可溶性PCP受体制剂含有谷氨酸识别位点,并且如电生理数据所提示的,可能代表PCP和NMDA的单一受体复合物。以活性结合形式成功溶解PCP受体现在应该有助于其纯化。